Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDA ...
56m
Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria") ...
The shortages were declared in August 2022. Meanwhile, Axios reports on how makers of copycat weight loss drugs are preparing for a crackdown. In medical tech and pharma news: a pacemaker recall, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback